Device Trial Radar · NCT05714501
Millipede AspiRation for Revascularization in Stroke (MARRS) Study
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
235
Actual
Start
Oct 9, 2023
Primary completion
Mar 8, 2025
Study completion May 12, 2025
Sponsor
- Lead sponsor
- PerfuzeNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of the study are to examine the performance and safety characteristics of the Millipede System when used for revascularization of patients with acute ischemic stroke due to Large Vessel Occlusions (LVOs) and to record associated clinical outcomes.
Conditions
- Acute Ischemic Stroke
Interventions
Millipede SystemDevice
Mechanical thrombectomy
Primary outcomes
What the sponsor says the trial is designed to measure.
- ITT Cohort: Rate of Core Lab-adjudicated Reperfusion Success Within Three PassesTime frame: Intraprocedural
- ITT Cohort: Primary Safety OutcomeTime frame: From Day 0 (procedure) through to the 90 Day visit.
- ITT Cohort: Supplementary Analysis of Primary Effectiveness EndpointTime frame: Intraprocedural
3 more outcomes with a free account
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
Yale University Hospital
New Haven, Connecticut
Baptist Health Research Institute
Jacksonville, Florida
Tampa General Hosital
Tampa, Florida
20 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.